Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 1, Pages 15-30Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm301448p
Keywords
-
Categories
Funding
- U.S. National Institutes of Health, NIH [DP1OD006933/DP1CA174419]
- ARRA stimulus Grant [RC2A148375]
- NCI SPORE grant in breast cancer [P50CA098131]
- American Cancer Society [PF1110501CDD]
- NIH SIG Grant [1S-10RR025677-01]
- Vanderbilt University
- U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]
- Michigan Technology Tr-Corridor [085P1000817]
- Michigan Economic Development Corporation [085P1000817]
Ask authors/readers for more resources
Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of proteins, is overexpressed and amplified in various cancers and promotes the aberrant survival of tumor cells that otherwise would undergo apoptosis. Here we describe the discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified two chemically distinct hit series that bind to different sites on Mcl-1. Members of the two fragment classes were merged together to produce lead compounds that bind to Mcl-1 with a dissociation constant of <100 nM with selectivity for Mcl-1 over Bcl-xL and Bcl-2. Structures of merged compounds when complexed to Mcl-1 were obtained by X-ray crystallography and provide detailed information about the molecular recognition of small-molecule ligands binding Mcl-1. The compounds represent starting points for the discovery of clinically useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available